ATE428719T1 - Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors - Google Patents

Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors

Info

Publication number
ATE428719T1
ATE428719T1 AT00948923T AT00948923T ATE428719T1 AT E428719 T1 ATE428719 T1 AT E428719T1 AT 00948923 T AT00948923 T AT 00948923T AT 00948923 T AT00948923 T AT 00948923T AT E428719 T1 ATE428719 T1 AT E428719T1
Authority
AT
Austria
Prior art keywords
nucleic acid
hgf
acid ligands
factor
growth factor
Prior art date
Application number
AT00948923T
Other languages
English (en)
Inventor
Judy Ruckman
Larry Gold
Andrew Stephens
Nebojsa Janjic
Ross Rabin
Michael Lochrie
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/364,543 external-priority patent/US6331394B1/en
Priority claimed from US09/364,539 external-priority patent/US6344321B1/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE428719T1 publication Critical patent/ATE428719T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT00948923T 1999-07-29 2000-07-24 Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors ATE428719T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/364,543 US6331394B1 (en) 1991-06-10 1999-07-29 Nucleic acid ligands to integrins
US09/364,539 US6344321B1 (en) 1990-06-11 1999-07-29 Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
PCT/US2000/020139 WO2001009159A1 (en) 1990-06-11 2000-07-24 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins

Publications (1)

Publication Number Publication Date
ATE428719T1 true ATE428719T1 (de) 2009-05-15

Family

ID=40577369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948923T ATE428719T1 (de) 1999-07-29 2000-07-24 Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors

Country Status (3)

Country Link
US (3) US20030049644A1 (de)
AT (1) ATE428719T1 (de)
DE (1) DE60042021D1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389710B2 (en) * 2004-02-27 2013-03-05 Operational Technologies Corporation Therapeutic nucleic acid-3′-conjugates
FR2867784B1 (fr) * 2004-03-17 2006-06-09 Commissariat Energie Atomique Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications
KR20080036595A (ko) * 2005-07-05 2008-04-28 가부시키가이샤 리보믹 면역글로불린 ｇ에 결합하는 핵산과 그 이용법
CA2646620C (en) * 2006-03-20 2015-07-14 Seikagaku Corporation Therapeutic agent for rheumatoid arthritis
JP4698559B2 (ja) * 2006-11-24 2011-06-08 Ｎｅｃソフト株式会社 ウサギ由来のＩｇＧ抗体に結合性を有する核酸分子
MY183404A (en) 2006-12-19 2021-02-18 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
CN102137939A (zh) * 2008-08-29 2011-07-27 霍夫曼-拉罗奇有限公司 不依赖vegf的肿瘤的诊断和治疗
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
US8236570B2 (en) * 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US8841429B2 (en) * 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
SI2536748T1 (sl) 2010-02-18 2014-12-31 Genentech, Inc. Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
US20140148503A1 (en) * 2011-07-20 2014-05-29 University Of Iowa Research Foundation Nucleic acid aptamers
WO2013043715A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
BR112016024319B1 (pt) 2014-04-18 2024-01-23 Acceleron Pharma Inc USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MA53400A (fr) 2015-04-06 2021-08-04 Acceleron Pharma Inc Hétéromultimères alk7: actriib et leurs utilisations
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
US9884900B2 (en) 2015-08-04 2018-02-06 Acceleron Pharma Inc. Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
PL3496739T3 (pl) 2016-07-15 2021-10-11 Acceleron Pharma Inc. Kompozycje zawierające polipeptydy actriia do stosowania w leczeniu nadciśnienia płucnego
MX2019001043A (es) 2016-07-27 2019-09-26 Acceleron Pharma Inc Metodos y composiciones para el tratamiento de la mielofibrosis.
EP3522934A4 (de) 2016-10-05 2020-04-15 Acceleron Pharma Inc. Zusammensetzungen und verfahren zur behandlung von nierenerkrankungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2584613B2 (ja) * 1985-03-30 1997-02-26 バリベ、マール 組換えｄｎａ技術によってｄｎａ、ｒｎａ、ペプタイド、ポリペプタイド、または蛋白質を取得するための方法
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5837834A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US5731424A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US6270472B1 (en) * 1998-12-29 2001-08-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Apparatus and a method for automatically introducing implants into soft tissue with adjustable spacing
US20020165188A1 (en) * 1999-10-14 2002-11-07 Meenhard Herlyn Methods for inhibition of tumorigenic properties of melanoma cells

Also Published As

Publication number Publication date
US20090075922A1 (en) 2009-03-19
US20030049644A1 (en) 2003-03-13
US20060148748A1 (en) 2006-07-06
DE60042021D1 (de) 2009-05-28

Similar Documents

Publication Publication Date Title
ATE428719T1 (de) Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
Streit et al. A role for HGF/SF in neural induction and its expression in Hensen’s node during gastrulation
CR6392A (es) Moduladores de ccr5
DE69635671D1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
Melamed et al. A functional B cell receptor transgene allows efficient IL-7-independent maturation of B cell precursors.
YU40701A (sh) Piperidini kao modulatori ccr5
DE69941429D1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
DE69931930D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
PA8429901A1 (es) Compuestos antipicornavirales y metodos para su uso y preparacion
Li et al. Ultrasound irradiation combined with hepatocyte growth factor accelerate the hepatic differentiation of human bone marrow mesenchymal stem cells
BR0010702A (pt) Novas quinonas como terapias de doenças
TR200402529T4 (tr) Yeni Fenalliloksi fenil türevleri.
Hassanpour et al. A reversal of age-dependent proliferative capacity of endothelial progenitor cells from different species origin in in vitro condition
EA200200625A1 (ru) Антипикорнавирусные соединения и композиции, их фармацевтическое применение и вещества для их синтеза
Jiang et al. Hematopoietic stem cells in neural-crest derived bone marrow
Douagi et al. Lymphocyte commitment during embryonic development, in the mouse
ATE361993T1 (de) Diagnose und behandlung von prostatakrebs
DE69634499D1 (de) Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration
D'Rozario et al. Fibroblastic reticular cells provide a supportive niche for lymph node–resident macrophages
DE60238945D1 (de) Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist
ATE375389T1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
Chen et al. A possible contribution of retinoids to regulation of fetal B lymphopoiesis
GB9610281D0 (en) Diagnostic method and apparatus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties